GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.…
GT Biopharma Reports Third Quarter 2026 Financial Results
GT Biopharma (NASDAQ: GTBP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.960 USD on 20 November 2026, down 80.9% over 52 weeks. Its 52-week range is 2.869 USD to 28.75 USD: the price is 89.7% below the high and 3.2% above the low.
Its market capitalisation is 6.33M USD.
GT Biopharma reports return on equity of -490.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.92M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.